HDM2 regulation by AURKA promotes cell survival in gastric cancer.

Clin Cancer Res

Authors' Affiliations: Departments of Surgery and Cancer Biology, Vanderbilt University Medical Center; Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, Tennessee; Translational Medicine, Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; and Department of Pharmacology, Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, New York.

Published: January 2014

AI Article Synopsis

  • Scientists studied two proteins, AURKA and HDM2, to understand how they affect another important protein called P53, which helps stop cancer cells from growing.
  • They found that when AURKA levels are high, it increases the amount of HDM2, which then makes P53 less effective, allowing cancer cells to survive and grow.
  • By using a special drug to block AURKA, they noticed that it helped improve P53 function, leading to lower survival rates of cancer cells in their experiments.

Article Abstract

Purpose: Suppression of P53 (tumor protein 53) transcriptional function mediates poor therapeutic response in patients with cancer. Aurora kinase A (AURKA) and human double minute 2 (HDM2) are negative regulators of P53. Herein, we examined the role of AURKA in regulating HDM2 and its subsequent effects on P53 apoptotic function in gastric cancer.

Experimental Design: Primary tumors and in vitro gastric cancer cell models with overexpression or knockdown of AURKA were used. The role of AURKA in regulating HDM2 and cell survival coupled with P53 expression and activity were investigated.

Results: Overexpression of AURKA enhanced the HDM2 protein level; conversely, knockdown of endogenous AURKA decreased expression of HDM2 in AGS and SNU-1 cells. Dual co-immunoprecipitation assay data indicated that AURKA was associated with HDM2 in a protein complex. The in vitro kinase assay using recombinant AURKA and HDM2 proteins followed by co-immunoprecipitation revealed that AURKA directly interacts and phosphorylates HDM2 protein in vitro. The activation of HDM2 by AURKA led to induction of P53 ubiquitination and attenuation of cisplatin-induced activation of P53 in gastric cancer cells. Inhibition of AURKA using an investigational small-molecule specific inhibitor, alisertib, decreased the HDM2 protein level and induced P53 transcriptional activity. These effects markedly decreased cell survival in vitro and xenograft tumor growth in vivo. Notably, analysis of immunohistochemistry on tissue microarrays revealed significant overexpression of AURKA and HDM2 in human gastric cancer samples (P < 0.05).

Conclusion: Collectively, our novel findings indicate that AURKA promotes tumor growth and cell survival through regulation of HDM2-induced ubiquitination and inhibition of P53. Clin Cancer Res; 20(1); 76-86. ©2013 AACR.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947328PMC
http://dx.doi.org/10.1158/1078-0432.CCR-13-1187DOI Listing

Publication Analysis

Top Keywords

cell survival
16
gastric cancer
16
hdm2 protein
16
aurka
14
hdm2
12
aurka promotes
8
p53
8
role aurka
8
aurka regulating
8
regulating hdm2
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!